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Abstract
Growth factors and certain oncogenes activate a range of phospholipid-mediated signal transduction pathways resulting
 .in cell proliferation. Demethoxyviridin DMV , a structural analogue of wortmannin and recently reported as a potent
inhibitor of phosphoinositide-3-kinase, inhibited bombesin plus insulin-stimulated increase in cell number in Swiss 3T3
cells, a model of cell proliferation. The drug produced cytostatic effects at concentrations below 1 mM and cytotoxic effects
at 10 mM. In intact Swiss 3T3 cells DMV inhibited insulin-stimulated PI 3- and 4-kinases and bombesin-stimulated
phospholipases C, D and A in the nanomolar range. DMV also inhibited bombesin-stimulated tyrosine phosphorylation of2
a range of proteins at nM concentrations. This study shows that DMV inhibited multiple stimulated signalling pathways
which lead to increased Swiss 3T3 cell proliferation. A stable analogue of DMV may have chemotherapeutic potential.
q 1997 Elsevier Science B.V.
Keywords: Wortmannin; Demethoxyviridin; Signal-transduction; Cell-proliferation; Phospholipases
1. Introduction
The stimulation of cell proliferation by growth
factors involves the activation of intracellular sig-
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nalling pathways. Many oncogene products are also
components of intracellular signalling pathways and
it is generally thought that specific inhibitors of these
pathways may have therapeutic use as novel anti-pro-
w xliferative agents 1,2 . A range of studies have
demonstrated that the stimulation of cells by growth
factors leads to activation of a number of membrane
associated phospholipases, resulting in the hydrolysis
of certain phospholipids. The hydrolysis of phos-
 .phatidylinositol 4,5-bisphosphate PIP by phospho-2
 .lipase C PI–PLC generates two second messengers,
inositol 1,4,5-trisphosphate and sn-1,2-diacylglycerol
which increase the intracellular calcium concentration
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w xand activate protein kinase C 3–5 . PIP can also be2
phosphorylated by growth factor stimulated phospho-
 .inositide 3-kinase PI 3-kinase to generate the puta-
tive second messenger phosphatidylinositol 3,4,5-tri-
 . w xsphosphate PIP 6 . PI 3-kinase has been shown to3
be associated with cellular complexes of growth fac-
w xtor receptors and certain oncogenes 7,8 . Phos-
 .phatidylcholine PC is also hydrolysed in response
to growth factor stimulation. The lipid can be hydrol-
 .ysed by a phospholipase D PLD to produce phos-
 .phatidate PA and choline or a phospholipase A 2
 .PLA to generate arachidonate and lysophosphati-2
w xdylcholine 9–11 . PA and arachidonate are also be-
lieved to have intracellular messenger functions.
Despite intensive investigation, potent and specific
inhibitors of phospholipid mediated signalling events
have not been available. However it was reported that
in human neutrophils, the fungicidal metabolite wort-
mannin 1,6bb ,7,8,9a,10,11,11b-octahydro-11-hy-
 . wdroxy-1- methoxymethyl -9ab-dimethyl-3H-furo 4,-
x w x w x .3,2-de indeno 4,5-h 2 benzopyran-3,6,9-trione and
its structural analogue demethoxyviridin DMV;
.structures are shown in Fig. 1 , inhibited fMet-Leu-
Phe-stimulated superoxide generation, PLD activity
w xand less potently PI–PLC activity 12 . Subsequently,
it has been demonstrated that wortmannin and DMV
can function as more potent inhibitors of PI 3-kinase
w x w x13,14 and very recently of phospholipase A 15 .2
Although wortmannin and DMV have been reported
w xas specific PI 3-kinase inhibitors 16,17 , the data
indicate that wortmannin and DMV may have a
broad range of specificities in the inhibition of phos-
pholipid mediated signal transduction.
Using the well characterised Swiss 3T3 cell as a
model system, we have examined the effects of DMV
upon the multiple lipid signalling pathways and pro-
liferation that is stimulated in these cells by bombesin
Fig. 1. Structures of demethoxyviridin and wortmannin.
and insulin. Our results demonstrate that DMV func-
tions as an inhibitor of phospholipases, inositol lipid
kinases and tyrosine phosphorylation and has a cyto-
static effect on proliferating Swiss 3T3 cells.
2. Materials and methods
2.1. Materials
Bombesin and wortmannin were from Sigma, UK,
human insulin from Novo, Denmark. Tissue culture
media was from Gibco–BRL. Thin layer chromatog-
raphy plates and HPLC columns were from What-
man. DMV was provided by Smith Kline Beecham,
UK. Lipids were from Lipid Products, Nutley, Sur-
w3 xrey. H Inositol phosphate standards were from
DuPont NEN, other radiochemicals were from Amer-
sham International.
2.2. Cell culture
Swiss 3T3 fibroblasts were maintained in Dul-
 .becco’s modified Eagle’s medium DMEM supple-
 .  .mented with 10% vrv newborn-calf serum NBCS .
A431 epidermoid carcinoma cells were maintained in
 .HAM’s F-10rDMEM 50 : 50 vrv supplemented
 .  .with 10% vrv foetal calf serum FCS . A2780
ovarian carcinoma cells were maintained in RPMI
 .1640 medium supplemented with 10% vrv FCS.
All cells were grown at 378C in a humidified atmo-
 .sphere of airrCO 19 : 1 .2
2.3. Measurement of cell proliferation
Swiss 3T3 cells were plated at a density of 2=
4  .10 rml, in DMEM containing 3.5% vrv NBCS.
After 24 h the medium was replaced with serum-free
 .DMEM containing bombesin 6.7 nM and insulin
 .  .1 mgrml . Demethoxyviridin DMV , disolved in
DMSO, was added directly. Control cells received
 .0.5% vrv DMSO which was without effect on cell
growth. Cells were trypsinised daily and counted in a
Coulter counter. For clonogenic analysis of IC con-50
centration, cells were plated and treated as above.
After 24 h cells were trypsinised and plated at a
density of 1000 cells per 6 cm petri dish in DMEM
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 .containing 10% vrv NBCS. After eight days
colonies were fixed, stained and counted. The IC50
was the concentration required to reduce the number
of colonies to 50% of the control.
[51 ]2.4. Measurement of Cr release
Swiss 3T3 cells were trypsinised, resuspended in
 .DMEM containing 0.1% wrv BSA and incubated
w51 xwith 1 mCirml Cr at 378C for 1.5 h. They were
washed, resuspended in fresh medium and seeded at
5=104rwell into 96-well plates. DMV was added
and the cells incubated for 3 h at 378C. The plates
were centrifuged and aliquots of the supernatant re-
moved and the radioactivity determined. Total ra-
dioactivity was determined in cells lysed with 0.5%
 .vrv Triton X-100.
2.5. Immunoblotting of p53
Exponentially growing A2780 cells were treated
with cisplatin or DMV for 24 h. Cells were lysed and
the solubilised proteins seperated by SDS-PAGE,
transferred to nitrocellulose and probed with the
pAB-2 anti-p53 antibody, as previously described
w x18 .
2.6. Phospholipase assays in intact cells
PI–PLC activity was assessed in bombesin-stimu-
w3 xlated cells labelled with 1 mCirml H inositol by
w3 xdetermining the generation of H inositol phosphates
in the presence of 10 mM LiCl, following separation
by anion exchange chromatography. PLD activity
was assessed in bombesin-stimulated cells labelled
w3 xwith 4 mCirml H palmitate by determining the
w3 xgeneration of H phosphatidylbutanol in the pres-
ence of 30 mM butanol following separation by thin
layer chromatography. PLA activity was assessed in2
bombesin-stimulated cells labelled with 1 mCirml
w3 xH arachidonate, by determining the release of
w3 xH arachidonate from phospholipids following sepa-
w xration by thin layer chromatography 15 .
[32 ]2.7. Measurement of P -labelled lipids
Swiss 3T3 cells were grown to confluence in
25 cm2 flasks and quiesced in DMEM containing 2%
 .vrv NBCS for 24 h. Cells were washed twice with
 .phosphate-free DMEM containing 0.1% wrv fatty
acid-free bovine serum albumin and 20 mM Hepes,
pH 7.4, and labelled for 90 min with 0.25 mCirml
w32 xP phosphate. Following stimulation, lipids were
extracted, deacylated and deglycerated and the water
soluble phosphates were separated by anion exchange
w xHPLC as previously described 15 .
2.8. Analysis of tyrosine phosphorylated proteins
Swiss 3T3 cells were grown to approximately 80%
confluence in 6-well plates and quiesced in DMEM
 .containing 2% vrv NBCS for 24 h. A431 cells
were grown to approximately 80% confluence in
2  .25 cm flasks in HAM’s F-10rDMEM 50 : 50 vrv
 .containing 10% vrv FCS. The medium was then
replaced with serum-free HAM’s F-10rDMEM
 .50 : 50 vrv for 24 h. Swiss 3T3 cells were washed
in HHBG and stimulated with bombesin. A431 cells
 .were washed in HAM’s F-10rDMEM 50 : 50 vrv
 .containing 0.1% wrv BSA and stimulated with
EGF. Cells were lysed and the solubilised proteins
separated by SDS-PAGE, transferred to nitrocellulose
and probed with the PY54 anti-phosphotyrosine anti-
w xbody, as previously described 19 .
2.9. Measurement of EGF receptor kinase acti˝ity
EGF receptor was partially purified from A431
cell lysates by wheat germ agglutinin chromatogra-
phy. Partially purified EGF receptor was preactivated
 .with EGF 10 mgrml for 20 min at 48C. The EGF
 .receptor substrate, poly Glu – Ala – Tyr6 3
 . 0.04 mgrml , was incubated in kinase buffer 20 mM
Hepes, pH 7.6, 100 mM sodium orthovanadate, 0.02%
 .  .wrv Triton X-100, 2% vrv glycerol, 25 mM
.MgCl and 1 mM MnCl containing 1 mM ATP and2 2
w 32 x0.05 mCi g- P ATP. DMV was added and the reac-
tion initiated by addition of the preactivated EGF
 .receptor 10 mg per assay . Reactions were termi-
nated by the addition of ice-cold 0.5 mM ATP. A
volume of the reaction mixture was spotted onto
3MM paper strips which were washed for 3=30 min
 .in ice-cold 10% wrv TCA containing 0.01 M
sodium pyrophosphate. The paper strips were air
dried and radioactivity determined by liquid scintilla-
tion counting.
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( )2.10. Preparation of demethoxy˝iridin DMV and
wortmannin.
DMV and wortmannin were dissolved in fresh
DMSO. For the phospholipase and phosphotyrosine
studies, the inhibitors were diluted in HHBG prior to
immediate addition to the cells. For analysis of
w32 xP labelled lipids, DMV was diluted in phosphate
free DMEM buffer. A 5 min preincubation with in-
hibitor was used prior to addition of agonist in these
assays.
Incubation of DMV with tissue culture medium for
1 h prior to addition to Swiss 3T3 cells dramatically
reduced the potency of the compound in inhibiting
cell growth. Thus the drug had only limited stability
in aqueous solution and it has been suggested that
w xDMV may be sensitive to hydrolytic destruction 14 .
3. Results
3.1. Effect of DMV on agonist-stimulated inositol
lipid le˝els
The most frequently reported effect of wortmannin
and DMV upon lipid mediated signalling is the inhi-
bition of PI 3-kinase activity either in vitro or in vivo
w x1,14 . PI 3-kinase is activated by a range of growth
factors and oncogenes and it has been proposed that
this may be important for mitogenesis and cell trans-
w x 32formation 8 . In Pi-labelled Swiss 3T3 cells
w32 x  .Fig. 2. Anion exchange HPLC profile of the deacylated and deglycerated products derived from P Pi-labelled Swiss 3T3 cells. A
 .  .  .unstimulated cells; B cells stimulated with 100 nM bombesin for 30 s; C cells stimulated with 10 mgrml insulin for 5 min; and D
cells preincubated for 5 min with 1 mM DMV prior to stimulation with 10 mgrml insulin for 5 min. The results are typical of two separate
 .  .  .experiments.Numbering of peaks: 1sPhosphatidylinositol PI ; 2sPhosphatidic Acid PA ; 3sPhosphatidylinositol 4-phosphate PIP ;
 .  .4sPhosphatidylinositol 4,5-bisphosphate PIP ; and in the inset, 5sPhosphatidylinositol 3,4,5-trisphosphate PIP . Xspeak of2 3
w32 xunknown identity. Peaks are the P labelled head group representing the deacylated and deglycerated lipid.
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bombesin did not stimulate PI 3-kinase activity, as
demonstrated by examining changes in 3-phosphory-
  .  ..lated lipids Fig. 2 a and b . Bombesin stimulated
w32 x the generation of P -phosphatidylinositol PI; Peak
. w32 x  .1 and P -PA Peak 2 , which is consistant with
bombesin having activated phosphoinositide turnover.
However, insulin stimulated PI 3-kinase activity in
Swiss 3T3 cells when determined by the generation
w32 x   .  ..of P -PIP Peak 5; compare Fig. 2 a and c .3
w32 xInsulin also stimulated the incorporation of Pi into
 .   ..PIP Peak 3 and PIP Peak 4; Fig. 2 c , but had no2
effect upon the labelling of PI or PA. Quantitation of
these effects of insulin upon inositol phospholipid
labelling is presented in Table 1. Preincubation of the
cells with 1 mM DMV completely inhibited insulin-
  .stimulated PIP generation compare Fig. 2 c and3
 ..d and reduced the amounts of PIP and PIP. 0.1 nM2
DMV had only marginal effects upon the insulin-
w32 xstimulated changes in Pi incorporation into the
lipids, but at a DMV concentration of 10 nM, the
insulin-stimulated PIP and PIP levels were both3
 .inhibited by approximately 50% Table 1 . DMV also
reduced the amount of radioactivity associated with
Peak X, whose identity is unclear, but it may repre-
sent choline phosphate.
Table 1
Effect of DMV on the levels of 32P-labelled inositol lipids in
insulin-stimulated Swiss 3T3 cells
32w x  .P labelled lipid cpm
 .  .PI PI4P PI 4,5 P PI 3,4,5 P2 3
Basal 7417 12924 26906 12
"204 "1078 "1469 "2
Insulin 6847 19015 32558 295
"979 "1088 "1836 "15
Insulin 6025 3174 24564 10
 .qDMV 1mM
Insulin 6052 14936 27418 144
 .qDMV 10 nM "1338 "505 "1620 "15
Insulin 7014 18557 34701 237
 .qDMV 0.1 nM
Basal 8707 10188 28627 18
 .qDMV 1mM
w32 xSwiss 3T3 cells were prelabelled with P Pi, washed and
 .stimulated with insulin 10 mgrml for 5 min at 378C. DMV
 .10 nM was added 5 min prior to stimulation with insulin. Incu-
bations were terminated and lipids extracted and analysed as
described in Section 2. The values shown are cpm for individual
measurements or cpm " range for two independent flasks of
cells.
3.2. Effect of DMV on bombesin-stimulated
phospholipase acti˝ation
DMV was originally shown to be a potent inhibitor
of fMet-Leu-Phe-stimulated PLD in the human neu-
 . w xtrophil IC s31 nM 12 . Inhibition of PI-PLC ac-50
tivity in the same cells required concentrations almost
10-fold higher.
In Swiss 3T3 cells DMV inhibited 60% of the
bombesin-stimulated PLD activity with an IC of50
  ..approximately 50 nM Fig. 3 a . Bombesin-stimu-
lated PLD activity in Swiss 3T3 cells appears to be
regulated by the activation of both protein kinase C
 . w xPKC and tyrosine kinases 19 . The activation of
PKC is a post-receptor effect stimulated by the gener-
ation of diacylglycerol derived from PIP hydrolysis.2
Consequently, it was possible that the inhibition of
PLD activity was due to the inhibition of PI–PLC
activity. Therefore the effect of DMV upon
bombesin-stimulated PI–PLC activity was examined
 .in Swiss 3T3 cells. Fig. 3 b shows that DMV inhib-
ited approximately 90% of the bombesin-stimulated
PI–PLC activity with an IC of 30 nM.50
In addition to PI–PLC and PC–PLD, bombesin
stimulates PLA activity in Swiss 3T3 cells. In cells2
w3 xlabelled with H arachidonic acid, DMV inhibited
bombesin-stimulated arachidonate generation, a mea-
sure of PLA activation, with an apparent IC value2 50
  ..of 2.1 nM Fig. 3 c . DMV had no effect upon basal
 .phospholipase activity results not shown .
3.3. Effect of DMV on tyrosine phosphorylation
Wortmannin has been reported to affect the protein
phosphorylation catalaysed by myosin light chain
w xkinase 20 . However growth factors stimulate mito-
genic cascades, in part, by activating protein tyrosine
phosphorylation, catalysed by either intrinsic receptor
kinases or members of the src-related tyrosine kinase
w xfamily 21,22 . Therefore we determined the effect of
DMV on bombesin-stimulated tyrosine phosphoryla-
tion in Swiss 3T3 cells. As we have previously
w xreported 19 , bombesin stimulated a small but rapid
increase in the tyrosine phosphorylation of a range of
proteins via the activation of cytosolic tyrosine ki-
nases. Fig. 4 shows an increase in phosphorylation of
proteins corresponding to molecular masses of ap-
proximately 120–130 kDa, 90 kDa, 65–70 kDa, 60–
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Fig. 3. Inhibition of bombesin-stimulated phospholipase activa-
tion in Swiss 3T3 cells by DMV. Radiolabelled cells were
princubated for 5 min with DMV prior to stimulation with 100nM
bombesin, phospholipase activity was determined as described in
 .  .Section 2. A effect of DMV on PC–PLD activity; B effect of
 .DMV on PI–PLC activity; and C effect of DMV on PC–PLA 2
activity. The results are expressed as % inhibition compared to
 .maximal activity in the absence of inhibitor, mean"S.D., ns3
from a single experiment representative of three.
65 kDa, 42 kDa and 38 kDa, following a 2 min
bombesin-stimulation. The proteins of molecular mass
90 kDa and 42 kDa were only transiently phosphory-
lated with the levels returning to basal by 5 min,
whilst the phosphorylation of the other proteins was
 .sustained for at least 60 min data not shown . DMV
partially inhibited the bombesin-stimulated increase
Fig. 4. Inhibition of bombesin-stimulated tyrosine phosphoryla-
tion. Cells were preincubated for 5 min with various concentra-
tions of DMV prior to stimulation for 2 min with 10 nM bombesin.
Cells were lysed, proteins separated by SDS-PAGE and probed
for phosphotyrosine as described in Section 2. The numbered
lanes in the photograph correspond to lysates from cells treated
as follows: 1, basal control; 2, bufferqbombesin; 3, 10 mM
DMVqbombesin; 4, 1mM DMVqbombesin; 5, 100nM DMV
qbombesin; 6, 10 nM DMVqbombesin; 7, 1 nM DMVq
bombesin; 8, 0.1 nM DMVqbombesin; 9, 0.01 nM DMVq
bombesin.
Fig. 5. Effect of DMV on receptor tyrosine kinase activity.
Partially purified EGF receptor was incubated with increasing
concentrations of DMV. Kinase activity was determined as de-
scribed in Section 2.
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in the tyrosine phosphorylation of all proteins over
 .the concentration range of 10 nM to 10 mM Fig. 4 .
It would appear from the results shown in Fig. 4
that the inhibition of tyrosine phosphorylation by
DMV is inconsistent with a normal dose response
relationship, however it is important to note that the
stimulation of tyrosine phosphorylation by agonists
such as bombesin is small and variable in contrast to
that induced by a receptor tyrosine kinase. The effect
of DMV upon insulin receptor kinase activity was not
examined due to the low number of receptors present
on Swiss 3T3 cells. The insulin and EGF receptor
kinase domains are structurally and functionally ho-
w xmologous 23,24 , therefore the effect of DMV on
EGF receptor autophosphorylation and kinase activity
in A431 cells was examined. Inhibition of autophos-
Fig. 6. Effect of DMV on proliferation in Swiss 3T3 cells. Cells
 .were grown for 24 h in DMEM containing 3.5% vrv NBCS.
Cells were then stimulated with 6.7 nM bombesin plus 1mgrml
insulin in serum free DMEM. DMV was added directly to the
wells. Values are mean cell number=10-4 per well " S.E.M.,
 .where ns3 from a single experiment typical of three. I
 .  .control cells; e plus bombesin and insulin; ‘ bombesin and
 .insulin plus 10 mM DMV; ^ bombesin and insulin plus 1mM
 .  .DMV; \ bombesin and insulin plus 0.1mM DMV; x
bombesin and insulin plus 0.01mM DMV.
Fig. 7. Levels of p53 protein in A2780 cells following treatment
with DMV. Cells were incubated with drug for 24 h, lysed and
analysed by western blotting with a p53-specific antibody. The
numbered lanes in the photograph correspond to lysates from
cells treated as follows: 1, 0.1mM DMV; 2, 1mM DMV; 3,
10 mM DMV; 4, 5mM cisplatin; 5, untreated.
phorylation was only observed at high concentrations
 .data not shown , whilst DMV only inhibited the
EGF receptor catalysed phosphorylation of a syn-
thetic substrate at concentrations of 10 mM and above
 .Fig. 5 . Therefore, DMV does not function as a
non-specific inhibitor of receptor tyrosine kinases and
consequently the inhibition of insulin action is un-
likely to be at the level of the receptor.
3.4. Effect of DMV on cell growth
Bombesin is mitogenic for a wide variety of cells
w x25,26 and bombesin-like peptides can act as au-
w xtocrine mitogens for small cell lung carcinoma 27 .
In Swiss 3T3 cells bombesin and insulin are poor
w xmitogens 28 . However, when added in combination
 .there was significant mitogenesis Fig. 6 . This pre-
sumably reflects the requirement for the activation of
multiple signalling pathways for cells to proliferate.
DMV inhibited the proliferation of Swiss 3T3
cells, as determined by changes in cell number Fig.
.6 . A significant anti-proliferative effect was ob-
served at 10 nM DMV. At 1 mM and above, cell
proliferation was completely inhibited by DMV and a
cytotoxic effect was observed, which was confirmed
 .by clonogenic assay data not shown . The inhibition
was not restricted to Swiss 3T3 cells, since a range of
tumour cell lines demonstrated sensitivity to DMV
 .manuscript in preparation . The effect of DMV on
cell proliferation was probably not mediated through
DNA alkylation since we detected no upregulation of
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Table 2
Effect of DMV on 51Cr release in Swiss 3T3 cells
 .DMV concentration mM % Specific lysis
100 23.20"3.80
10 1.97"1.00
1 1.38"0.68
0.1 0.11"0.61
0.01 0.08"0.38
0.001 0.52"0.23
 .0 DMSO control 0.89"0.78
Swiss 3T3 cells prelabelled with 51Cr were incubated with vari-
ous concentrations of DMV for 4 h at 378C. Results are mean "
S.D., ns3 from a single experiment representative of two.
p53 expression, a measure of DNA damage, in DMV
 w x.treated A2780 cells Fig. 7; 29 . As a control cis-
platin caused a significant upregulation of p53 in the
 .same cells Fig. 7 . Thus the effects of DMV upon
cell growth in Swiss 3T3 cells were more likely due
to effects upon growth factor-stimulated signalling
pathways. Since cytotoxicity was observed at higher
drug concentrations, the effect of DMV upon mem-
w51 xbrane damage was assessed by the release of Cr
from pre-loaded cells. Cytolytic effects were only
observed at a concentration of 100 mM where 23% of
w51 x maximum possible Cr release was detected Table
.2 .
4. Discussion
Swiss 3T3 cells have provided an excellent model
sytem in which to study the regulation of growth
factor-stimulated lipid signalling and proliferation.
By examining inhibitors of signal transduction path-
ways as novel anti-proliferative agents, potential lead
compounds for chemotherapy may be identified
w x2,30 . However the majority of studies have reported
effects upon signalling pathways in isolation, for
example the effect of wortmannin on PI 3-kinase
w xactivity 1 . In contrast, we have examined multiple
signalling pathways and we demonstrate that in intact
Swiss 3T3 cells, DMV inhibited both the phospho-
lipid mediated signalling and the mitogenesis that is
stimulated by bombesin plus insulin. The lack of
effect upon membrane damage or p53 induction at
relevant DMV concentrations provides support for
inhibition of receptor-stimulated signalling being the
mechanism of DMV-induced anti-proliferative ef-
fects. This separates DMV from a large number of
currently used anti-proliferative chemotheraputic
compounds which function as DNA-alkylating agents
w x29 .
The data in this manuscript confirm that DMV is
w xan inhibitor of stimulated PI 3-kinase activity 14 .
The effect of DMV upon PI 3-kinase activity was
almost certainly direct, because this compound inhib-
ited the in vitro activity of this enzyme in immuno-
preciptates prepared from insulin stimulated fibrob-
w xlasts 15 . The results in Fig. 2 also demonstrate that
DMV inhibited insulin-stimulated PIP generation by
w32 x66% and the stimulated incorporation of P into
PIP by 91%. It is not clear whether these effects are2
direct or indirect, since the inhibition of PIP genera-2
tion may be a consequence of inhibition of PIP
generation. It has been recently reported that in
adrenal glomerulosa cells, wortmannin inhibited the
synthesis of the hormone-sensitive pools of PIP and
PIP and the activity of PI 4-kinase was reduced in2
w xadrenocortical extracts 31 . The PI 4-kinase activity
inhibited was a membrane associated form of the
enzyme, the other membrane bound forms were not
wortmannin sensitive. The importance of PI 4-kinase
in cell proliferation has been emphasised by the
demonstration of an increase in its activity in human
w xbreast and ovarian carcinoma cells 32 . In addition
the inhibition of OVCAR-5 cell proliferation by high
concentrations of quercetin was accompanied by an
w xinhibition of PI 4-kinase 33 .
Alternatively, it has been suggested that PIP 3-2
kinase activity is responsible for regulating the hor-
mone-responsive pool of PIP . It has been reported2
that PIP can activate the small molecular weight3
GTP-binding protein Rac, which recently has been
shown to stimulate PIP biosynthesis in fibroblasts2
w x w x34 and platelets 35 . Thus, the inhibition of PIP3
generation could be of importance in regulating a
number of PIP -dependent events.2
The effect of DMV upon PLA activity is also2
likely to be direct since in Swiss 3T3 cells, bombesin
stimulated PLA activity in the absence of PI 3-kinase2
activity. Only 60% of total cellular phospholipase D
activity was inhibited by DMV. This incomplete
effect may reflect the presence of more than one
isoform of this enzyme in cells, with only one being
DMV sensitive. Two PLD isoforms have been sepa-
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w xrated from rat brain 36 . Bombesin-stimulated PI–
PLC activity was totally inhibited by DMV in fibrob-
lasts. It is noteworthy that PLA , one form of PLD,2
PI–PLC and PI 3-kinase have all been reported to
w xhave a requirement for PIP . For PLA 37 and the2 2
w xPLD isoform 38 , PIP is used as a co-factor in the2
in vitro assay of both of these enzymes, although an
in vivo requirement is unclear. For PI-PLC and PI
3-kinase, PIP is the substrate in vivo. It is possible,2
therefore, that DMV functions as an inhibitor of PIP2
binding proteins or affects PIP availability.2
The inhibition of tyrosine kinase activity by DMV
may be another key aspect in the the anti-prolifera-
tive action of the drug. Whilst the mechanism of this
inhibition is unclear, it is possible that the inhibition
may play a role in regulating the phospholipases. A
role for tyrosine kinase activity in activating both
w x w xPLD 19 and PLA 39 has been described. In2
addition, the inhibition of tyrosine kinase activity
may be affecting other signalling pathways. The inhi-
bition of tyrosine kinases by DMV is not inconsistent
with its proposed role as a PIP inhibitor, if the2
catalytic site of the tyrosine kinases share structural
identities with PIP binding proteins.2
DMV acted only on the stimulated lipid signalling
pathways and was cytotoxic to proliferating cells. In
quiescent cells, DMV had no effect upon basal activi-
ties of the lipid metabolising enzymes studied here
 .and was not cytotoxic results not shown . Similarly
it has been shown that in NIH fibroblasts, wortman-
w xnin had no effect upon basal levels of PIP 1 . These3
data point to a mode of action of DMV which is
dependent upon cellular activation and suggest that
compounds such as DMV may be selective for highly
proliferative cellular states such as cancer. The differ-
ence in potency of DMV in causing the acute effects
upon signal transduction and the longer term effects
upon cellular proliferation may reflect the instability
w xof the compound in aqueous solution 14 .
Since growth factors and oncogenes activate a
plethora of signalling pathways, it may be that an
inhibitor of signal transduction pathways with a broad
range of specificities may render the cell inert to
enhanced stimuli associated with the transformed
phenotype. Thus, DMV could be a prototype for a
class of inhibitors which act upon inter-related lipid
signalling pathways to inhibit proliferation. Therefore
such drugs may effectively bypass the level of redun-
dancy present in the system. However, the use of
DMV or wortmannin for chemotherapeutic use will
remain limited until the development of more stable
analogues.
Acknowledgements
We would like to thank Dr. A. Turnell for helpful
discussion. This work was supported by grants from
the Cancer Research Campaign, the Medical Re-
search Council and the Wellcome Trust. AS was
supported by a BBSRC studentship with additional
financial support from Astra plc. PW acknowledges
the award of a Cancer Research Campaign Life Fel-
lowship.
References
w x1 G. Powis, R. Bonjouklian, M.M. Berggren, A. Gallegos, R.
Abraham, C. Ashendel, L. Zalkow, W.F. Matter, J. Dodge,
 .G. Grindley, C.J. Vlahos, Cancer Research 54 1994 2419–
2423.
w x  .2 A. Levitzki, Eur.J. Biochem. 226 1994 1–13.
w x  .3 M.J. Berridge, I. R.F., Nature, 341 1989 197–205
w x  .4 Y. Nishizuka, Science 258 1992 607–614.
w x  .5 Y. Nishizuka, FASEB J. 9 1995 484–496.
w x6 L.R. Stephens, T.R. Jackson, P.T. Hawkins, Biochim. Bio-
 .phys. Acta 1179 1993 27–75.
w x  .7 R. Kapeller, L.C. Cantley, Bioessays 16 1994 565–576.
w x8 L.C. Cantley, K.R. Auger, C. Carpenter, B. Duckworth, A.
 .Graziani, R. Kapeller, S. Soltoff, Cell 64 1991 281–302.
w x  .9 N. Divecha, R.F. Irvine, Cell 80 1995 269–278.
w x  .10 J.H. Exton, Biochim. Biophys. Acta 1212 1994 26–42.
w x11 M.J.O. Wakelam, New Targets for Cancer Chemotherapy,
CRC Press, 1994, pp. 31–44
w x12 R.W. Bonser, N.T. Thompson, R.W. Randall, J.E. Tateson,
G.D. Spacey, H.F. Hodson, L.G. Garland, Br. J. Pharama-
 .col. 103 1991 1237–1241.
w x  .13 A. Arcaro, M.P. Wymann, Biochem. J. 296 1993 297–301.
w x14 R. Woscholski, T. Kodaki, M. McKinnon, M.D. Waterfield,
 .P.J. Parker, FEBS Lett. 342 1994 109–114.
w x15 M.J. Cross, A. Steward, M.N. Hodgkin, D.J. Kerr, M.J.O.
 .Wakelam, J. Biol. Chem. 270 1995 25352–25355.
w x  .16 C.J. Vlahos, Drugs of the Future 20 1995 165–171.
w x17 M. Ui, T. Okada, J. Hazeki, O. Hazeki, Trends Biochem.
 .Sci. 20 1995 303–307.
w x18 R. Brown, C. Clugston, C. Burns, A. Edlin, P. Vasey, B.
 .Vojtesek, Int. J. Cancer 55 1993 678–684.
w x19 C.P. Briscoe, A. Martin, M. Cross, M.J.O. Wakelam,
 .Biochem. J. 306 1995 115–122.
( )M.J. Cross et al.rBiochimica et Biophysica Acta 1362 1997 29–3838
w x20 S. Nakanishi, S. Kakita, I. Takahashi, K. Kawahara, E.
Tsukuda, T. Sano, K. Yamada, M. Yoshida, H. Kase, Y.
 .Matsuda, J. Biol. Chem. 267 1992 2157–2163.
w x  .21 A. Ullrich, J. Schlessinger, Cell 61 1990 203–212.
w x22 K. Malarkey, C.M. Belham, A. Paul, A. Graham, A. McLees,
 .P. Scott, R. Plevin, Biochem J. 309 1995 361–375.
w x23 Y. Ebina, L. Ellis, K. Jarnagin, M. Edery, L. Graf, E.
Clauser, J.H. Ou, F. Masiarz, Y.W. Kan, I. Goldfine, D.
 .Roth, W.J. Rutter, Cell 40 1985 747–758.
w x24 H. Riedel, T.J. Dull, J. Schlessinger, A.A. Ullrich, Nature
 .324 1986 68–70.
w x25 J.C. Willey, J.F. Lechner, C.C. Harris, Exptl. Cell Res. 153
 .1984 245–248.
w x26 J. Nelson, M. Donnelly, B. Walker, J. Gray, C. Shaw, R.F.
 .Murphy, Br. J. Cancer 63 1991 933–936.
w x27 F. Cuttitta, D.N. Carney, J. Mulshine, T.W. Moody, J.
 .Fedorko, A. Fischler, J.D. Minna, Nature 316 1985 823–
826.
w x28 E. Rozengurt, J. Sinnet-Smith, Proc. Nat. Acad. Sci. U.S.A.
 .80 1983 2936–2940.
w x  .29 M. Fritsche, C. Haessler, G. Brandner, Oncogene 8 1993
307–318.
w x  .30 G. Powis, Seminars in Cancer Biology 3 1992 343–350.
w x31 S. Nakanishi, K.J. Catt, T. Balla, Proc. Nat. Acad. Sci.
 .U.S.A. 92 1995 5317–5321.
w x  .32 M.T. Rizzo, G. Weber, Cancer Research 54 1994 2611–
2614.
w x33 N. Prajda, R.L. Singhal, Y.A. Yeh, E. Olah, K.Y. Look, G.
 .Weber, Life Sci. 56 1995 1587–1593.
w x34 K.F. Tolias, L.C. Cantley, C.L. Carpenter, J. Biol. Chem.
 .270 1995 17656–17659.
w x35 J.H. Hartwig, G.M. Bokoch, C.L. Carpenter, P.A. Janmey,
 .L.A. Taylor, A. Toker, T.P. Stossel, Cell 82 1995 643–653.
w x36 D. Massenburg, J.-S. Han, M. Liyanage, W.A. Patton, S.G.
Rhee, J. Moss, M. Vaughan, Proc. Nat. Acad. Sci. U.S.A.
 .91 1994 11718–11722.
w x37 C.C. Leslie, J.Y. Channon, Biochim. Biophys. Acta 1045
 .1990 261–270.
w x38 A.H. Brown, S. Gutowski, C.R. Moomaw, C. Slaughter, P.
 .Sternweis, Cell 75 1993 1137–1144.
w x39 L.L. Lin, M. Wartman, A. Lin, J.L. Knopf, A. Seth, R.J.
 .Davis, Cell 72 1993 269–278.
